GPC1 and pancreatic neoplasm: Glypican‐1 (GPC1), a cell surface proteoglycan, was found to enrich circulating EVs (crEVs) in pancreatic cancer patients, and GPC1‐positve crEVs levels are predictive of disease‐specific survival.95